Get the Stockscreener App
1.78
0.56%
-0.01
After Hours:
1.71
-0.07
-3.93%
Dogwood Therapeutics Inc stock is traded at $1.78, with a volume of 84,083.
It is down -0.56% in the last 24 hours and up +28.99% over the past month.
Dogwood Therapeutics Inc is a development-stage biopharmaceutical company focused on developing new medicines to treat pain and neuropathy. The pipeline is focused on treating chronic neuropathic pain and neuropathy. The Company operates in one segment and is a pre-revenue, development-stage biopharmaceutical company focused on developing new medicines to treat pain and peripheral neuropathy associated with cancer.
See More
Previous Close:
$1.79
Open:
$1.77
24h Volume:
84,083
Relative Volume:
0.91
Market Cap:
$59.86M
Revenue:
-
Net Income/Loss:
$-34.26M
P/E Ratio:
-0.0942
EPS:
-18.9056
Net Cash Flow:
$-15.62M
1W Performance:
-3.78%
1M Performance:
+28.99%
6M Performance:
-72.70%
1Y Performance:
-66.03%
1-Day Range:
$1.724
$1.8276
1-Week Range:
$1.724
$1.8588
52-Week Range:
$1.28
$9.50
Dogwood Therapeutics Inc Stock (DWTX) Company Profile
Name
Dogwood Therapeutics Inc
Sector
Industry
Phone
(866) 620-8655
Address
44 MILTON AVENUE, ALPHARETTA
Compare DWTX vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
DWTX
Dogwood Therapeutics Inc
|
1.78 | 60.20M | 0 | -34.26M | -15.62M | -18.91 |
VRTX
Vertex Pharmaceuticals Inc
|
435.93 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.62 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.43 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Dogwood Therapeutics Inc Stock (DWTX) Latest News
Dogwood Therapeutics Q1 2026 Earnings: Narrower-Than-Expected Loss Amid Continued Preclinical DevelopmentEPS Growth Rate - Newser
PRODU - produ
DWTX Reiterated by HC Wainwright & Co. -- Price Target Maintained at $12.00 - GuruFocus
DWTX News | DOGWOOD THERAPEUTICS INC (NASDAQ:DWTX) - ChartMill
Dogwood launches 12-week extension study for pain drug Halneuron - Investing.com UK
Dogwood launches 12-week extension study for pain drug Halneuron By Investing.com - Investing.com Australia
Chemo nerve pain patients get 12-week access to non-opioid Halneuron trial - Stock Titan
Dogwood Therapeutics, Inc. Q1 2026 SEC 10-Q Filing – Financial Statements, Management Discussion, and Risk Factors - Minichart
Dogwood Therapeutics 1Q Rev $0.00 >DWTX - Moomoo
Armistice Capital (NASDAQ: DWTX) reports 9.99% Dogwood stake - Stock Titan
Dogwood Therapeutics 1Q 2026: Revenue $2.41M, EPS ($0.15) — 10-Q Summary - TradingView
Dogwood Therapeutics (Nasdaq: DWTX) posts Q1 2026 loss, flags cash risk - Stock Titan
Dogwood Therapeutics Announces First Quarter 2026 Financial Results - Sahm
DWTX Stock Price, Quote & Chart | DOGWOOD THERAPEUTICS INC (NASDAQ:DWTX) - ChartMill
Dogwood Therapeutics 1Q Loss $4.99M >DWTX - Moomoo
Dogwood Therapeutics Reports First Quarter 2026 Results and Progress on Pain Pipeline - citybuzz -
Dogwood Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Dogwood Therapeutics Reports Q1 2026 Results, Advances Halneuron® and SP16, and Secures $100M Antiviral Partnership 1 - Minichart
Dogwood Therapeutics (NASDAQ:DWTX) Beats EPS Estimates in Q1 2026, Phase 2b Trial on Track - ChartMill
DOGWOOD THERAPEUTICS ($DWTX) Releases Q1 2026 Earnings - Quiver Quantitative
Dogwood Therapeutics reports Q1 2026 net loss $5.0M, cash $13.2M, Halneuron Phase 2b on track - TradingView
Dogwood Therapeutics (DWTX) narrows Q1 loss and advances pain pipeline - Stock Titan
Dogwood Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Dogwood Therapeutics Q1 net loss narrows, no revenue reported - TradingView
DWTX: Pipeline advances, reduced net loss, and new partnership drive positive outlook for 2026 - TradingView
Chemo pain drug developer Dogwood lands FDA, NCI backing and $100M deal - Stock Titan
Dogwood Therapeutics : Corporate Presentation (Dogwood Therapeutics Non Confidential Corporate Update May 2026) - marketscreener.com
Dogwood Therapeutics Inc expected to post a loss of 26 cents a shareEarnings Preview - TradingView
TradingKey - TradingKey
DWTX Dogwood stock climbs 4.2% after pharmaceutical company posts massive earnings beat, EPS smashes estimates by 94%SPAC - Newser
What separates Dogwood (DWTX) from the pack? (Eye on Rally) 2026-05-08Pre Earnings - Newser
Dogwood Therapeutics to Report First Quarter 2026 Financial Results on Thursday, May 14, 2026 - The Manila Times
Analysts Offer Insights on Healthcare Companies: Dogwood Therapeutics (DWTX), NRX Pharmaceuticals (NRXP) and Immuneering (IMRX) - The Globe and Mail
[ARS] Dogwood Therapeutics, Inc. SEC Filing - Stock Titan
Big capital authorization vote ahead for Dogwood Therapeutics (NASDAQ: DWTX) - Stock Titan
Dogwood Therapeutics files to sell 28.04M shares of common stock for holders - MSN
Dogwood licenses IMC-1, IMC-2 antiviral assets to PRIDCor By Investing.com - Investing.com Canada
Dogwood licenses IMC-1, IMC-2 antiviral assets to PRIDCor - Investing.com
Dogwood Therapeutics Announces Worldwide Development and - GlobeNewswire
DWTX (Dogwood Therapeutics Inc.) posts far narrower Q4 2025 loss than consensus estimates, yet shares dip 4.47% today.Momentum Score - Cổng thông tin điện tử Tỉnh Sơn La
Dogwood licenses Long-COVID antiviral assets in pact worth up to $100M - Stock Titan
Dogwood Therapeutics, Inc. (DWTX) Advances SP16 Program with FDA Investigational New Drug Approval - Insider Monkey
5 Oversold Biotech Stocks to Invest In Now - Insider Monkey
Dogwood Therapeutics (DWTX) seeks approval to increase authorized shares to 195M - Stock Titan
Dogwood Therapeutics Announces FDA Acceptance of SP16 Investigational New Drug Application for the Treatment of Chemotherapy Induced Pain and Neuropathy - Sahm
Dogwood Therapeutics receives FDA clearance for SP16 pain trial By Investing.com - Investing.com Australia
Dogwood Therapeutics, Inc (NASDAQ:DWTX) Sees Large Increase in Short Interest - MarketBeat
Dogwood Therapeutics receives FDA clearance for SP16 pain trial - Investing.com
Dogwood Therapeutics Announces FDA Acceptance of SP16 - GlobeNewswire
Dogwood Therapeutics Inc Stock (DWTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.98%
0.12%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):